Veterinary Oncology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, veterinary oncology market size in 2026 is estimated at USD 1.95 billion, growing from 2025 value of USD 1.74 billion with 2031 projections showing USD 3.43 billion, growing at 11.98% CAGR over 2026-2031.

This report Segments the Industry Into by Treatment Modality (Radiotherapy, Surgery, and More), by Animal Type (Canine, Feline, and More), by Cancer Type (Lymphoma, Mast Cell Tumor, and More), and Geography. The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Veterinary Oncology Market Trends and Insights

Rising Prevalence of Companion-Animal Cancers

Nearly half of dogs over 10 years develop a neoplasm, a rate that keeps demand elevated for oncology services as preventive medicine lengthens life expectancy. Breed predispositions sharpen this need, with Golden Retrievers and Boxers exhibiting above-average lymphoma incidence. Earlier diagnosis now directs more cases into curative pathways, fuelling uptake of surgery, radiation, and emerging immunotherapies. Owners' growing willingness to pursue aggressive protocols reinforces long-run service intensity, especially in markets with mature insurance penetration.

Increasing Corporate & Academic R&D Funding in Veterinary Oncology

Pharmaceutical firms cite translational value between companion-animal tumors and human oncology, prompting expansion of dedicated biologics capacity. Elanco's USD 130 million Kansas facility emphasizes monoclonal antibody output for canine cancers. Universities add momentum; Virginia Tech's histotripsy studies seek non-invasive osteosarcoma solutions. Non-profits such as Morris Animal Foundation channel grants toward limb-sparing immunotherapies, accelerating clinical timelines and broadening protocol sophistication.

High Out-of-Pocket Costs for Owners Despite Insurance Gaps

Comprehensive protocols can range from USD 10,000 to USD 30,000, often exceeding insurance caps and forcing difficult affordability decisions. Coverage exclusions for pre-existing conditions leave policyholders responsible for a large share of expenses. As immunotherapies and precision treatments enter the market at premium price points, the cost disparity between basic and advanced care widens, tempering uptake among middle-income households.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Adoption of Advanced Imaging & Liquid-Biopsy Diagnostics
2. AI-Assisted Early-Screening Platforms Entering Clinical Use
3. Geographic Scarcity of Radiotherapy & Advanced Care Centers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Surgery secured 40.12% of global 2025 revenues, underscoring its role as a frontline curative option for solid tumors within the veterinary oncology market. Advances in intraoperative imaging and minimally invasive techniques enhance margin control while reducing recovery times. Concurrently, immunotherapy's 13.04% CAGR reflects successful commercial launches of autologous cellular vaccines and small-molecule immune modulators that complement existing standards of care. Radiotherapy continues to grow as stereotactic protocols cut total fractions from 18 to three, shrinking owner travel commitments. Chemotherapy retains value for systemic malignancies, though genetic profiling refines dosing to minimize toxicity.

The therapeutic toolbox is moving toward truly multimodal regimens that marry surgical debulking with adjuvant radiation and checkpoint inhibitor courses. Focused ultrasound and photodynamic approaches add minimally invasive options for deep-seated or anatomically delicate lesions and are gaining traction as costs fall. AI-guided treatment planning leverages tumor genomics and imaging data to match patients with high-response regimens, improving outcomes and supporting evidence-based reimbursement.

Complete Report Scope:

• By Treatment Modality
  • Radiotherapy
  • Surgery
  • Chemotherapy
  • Immunotherapy
  • Other Treatments (Laser, Photodynamic, Focused Ultrasound)
• By Animal Type
  • Canine
  • Feline
  • Equine
  • Other Companion Animals (exotics, small mammals)
• By Cancer Type
  • Lymphoma
  • Mast-Cell Tumour
  • Mammary & Squamous-Cell Carcinoma
  • Osteosarcoma
  • Hemangiosarcoma
  • Melanoma
  • Other Cancers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 53.76% of 2025 sales, underpinned by high companion-animal spend, dense specialist networks, and a regulatory framework that allows conditional product approvals to reach clinics quickly. The United States hosts the largest pool of boarded veterinary oncologists, and its insurers increasingly reimburse advanced modalities, shortening payback periods for clinic investments in linear accelerators and CT scanners. University-industry collaborations funnel breakthrough science into commercial pipelines, further entrenching regional leadership.

Asia-Pacific stands out as the fastest-growing territory, charting a 13.62% CAGR to 2031 as pet humanization scales across China's urban centers. Disposable income growth intersects with expanding private-clinic networks and rising awareness of pet insurance, narrowing care-access gaps. Japan's mature small-animal market drives early adoption of precision biologics, while Australia's research community pilots AI decision-support tools that gain regional traction. Hao-Animal, a Chinese start-up, recently opened Shanghai's first integrated oncology-imaging hub, signaling domestic capacity build-up.

Europe holds the second-largest share, buoyed by stringent animal welfare statutes that encourage proactive oncology care. Harmonized EMA procedures streamline continental drug launches, though divergent reimbursement policies create pricing complexity. Germany's robust veterinary R&D ecosystem pioneers isotope-guided surgery, and the UK accelerates clinical trials under dedicated veterinary-specific regulatory guidance. France and the Nordics prioritize minimally invasive therapies, reflecting cultural emphasis on quality-of-life metrics.

1. Zoetis
2. Elanco
3. Boehringer Ingelheim
4. IDEXX
5. Siemens Healthineers (Varian)
6. Accuray
7. PetCure Oncology
8. Nippon Zenyaku Kogyo (ZENOAQ)
9. Morphogenesis Inc.
10. Karyopharm Therapeutics
11. Regeneus Ltd
12. OHC (The One Health Company)
13. VetDC Inc.
14. Anivive Lifesciences
15. LiteCure LLC
16. Cutting Edge Laser Technologies
17. Aesculight LLC
18. Mars Petcare

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support